Xenetic Biosciences, Inc.
XBIOStock
$2.81−18.03%52W
Market Cap$7.10M
P/E—
Div yield—
Beta2.15
Price Chart
Favorite Metrics
Price vs S&P 500 (26W)33.24%
Price vs S&P 500 (4W)-7.01%
VGM Score72.07
Market Capitalization$7.10M
Analyst Recommendations
Nov 2025
Dec 2025
Jan 2026
Feb 2026
2.17
2.17
2.17
2.17
Industry Peers — Pharmaceuticals(563)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
XBIOXenetic Biosciences, Inc. | A | B | C | $2.81 |
| LLYEli Lilly & Co. | D | B | B | $1169.17 |
| JNJJohnson & Johnson | D | C | B | $249.97 |
| ABBVABBVIE INC. | D | C | B | $254.39 |
| MRKMerck & Co., Inc. | C | C | B | $127.63 |
| NVSNovartis AG | C | C | C | $152.73 |
| NVONovo-Nordisk A/S | C | B | C | $51.48 |
| AZNAstraZeneca PLC | C | B | C | $169.29 |
| ABTAbbott Laboratories | C | C | D | $98.83 |
| PFEPfizer Inc. | B | C | C | $25.14 |
| VRTXVertex Pharmaceuticals Inc | D | C | C | $486.03 |
About
Xenetic Biosciences Inc is a biopharmaceutical company developing DNase-based therapies for difficult-to-treat cancers. The company's proprietary DNase technology targets neutrophil extracellular traps (NETs) to enhance the effectiveness of existing cancer treatments and immunotherapies. Xenetic is advancing a systemic DNase program as an adjunctive therapy for pancreatic cancer and other metastatic solid tumors.